NRx Pharmaceuticals (NASDAQ:NRXP) PT Raised to $44.00 at Ascendiant Capital Markets

NRx Pharmaceuticals (NASDAQ:NRXP) had its price objective hoisted by Ascendiant Capital Markets from $43.00 to $44.00 in a research report report published on Thursday, Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, HC Wainwright raised their target price on shares of NRx Pharmaceuticals from $2.00 to $19.00 and gave the company a buy rating in a research note on Monday, August 5th.

NRx Pharmaceuticals Price Performance

NRXP opened at $1.72 on Thursday. The firm has a market capitalization of $18.41 million, a P/E ratio of -0.55 and a beta of 1.25. NRx Pharmaceuticals has a one year low of $1.59 and a one year high of $7.33. The company has a fifty day moving average price of $2.04 and a 200-day moving average price of $10.85.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its earnings results on Wednesday, August 14th. The company reported ($0.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.06. On average, analysts expect that NRx Pharmaceuticals will post -3.25 earnings per share for the current year.

Hedge Funds Weigh In On NRx Pharmaceuticals

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. AdvisorShares Investments LLC bought a new position in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 642,632 shares of the company’s stock, valued at approximately $296,000. AdvisorShares Investments LLC owned 0.75% of NRx Pharmaceuticals as of its most recent SEC filing. 4.27% of the stock is currently owned by institutional investors and hedge funds.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.